Sign inJoin waitlistJoin the waitlist

Ann Silk

Co-Director of the Merkel Cell Carcinoma Center of Excellence · Mass General Brigham

Credentials: · · · · · · ·

History

Merkel Cell Carcinoma Center of Excellence · Mass General Brigham
Present
Mass General Brigham
Present

University of Michigan Health
2011–2013
UPMC
2008–2011
University of Pittsburgh School of Medicine
2004–2008

Research

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Journal for ImmunoTherapy of Cancer · 2017 · 1,572 citations
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Journal for ImmunoTherapy of Cancer · 2016 · 296 citations
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
ESMO Open · 2022 · 289 citations

Emily Ruiz
30 papers
Manisha Thakuria
20 papers
HK
Howard Kaufman
17 papers
Janice Mehnert
17 papers
Jonathan Schoenfeld
15 papers
Karam Khaddour
15 papers · 15 as a fellow
Danielle Margalit
11 papers
NR
Nina Ran
10 papers · 10 as a fellow
Roy Tishler
10 papers
GH
Glenn Hanna
9 papers
CS
Chrysalyne Schmults
8 papers
EG
Emily Granger
8 papers

Grants

The Fourth International Merkel Cell Carcinoma Symposium
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R13
Contact PI · $25K · Dana-Farber Cancer Inst
2026–2027

Clinical trials

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Principal investigator · Recruiting · Phase 4
Dana-Farber Cancer Institute
2026–2032
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Principal investigator · Withdrawn · Phase 1
Ankyra Therapeutics, Inc
2025–2030
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
2021–2023
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2017–2027